Diagnostik und Therapie der pulmonalarteriellen Hypertonie

2022 wurden die Leitlinien zur Diagnostik und Therapie der pulmonalen Hypertonie (PH) der Europäischen Fachgesellschaften für Kardiologie und Pneumologie aktualisiert [1] – mit wichtigen Neuerungen zur hämodynamischen Definition sowie Diagnose und Therapie der PH. Dieser Beitrag gibt einen Überblick über Definition und Klassifikation der PH und geht danach auf die Risikostratifizierung und Therapie der pulmonalarteriellen Hypertonie (PAH) ein.

Abstract

2022, the updated guidelines for the diagnosis and treatment of pulmonary hypertension (PH) of the European Societies of Cardiology and Pneumology were published. This resulted in important innovations concerning the hemodynamic definition as well as diagnosis and therapy of PH. In the following, an overview of the definition and classification of PH will be given, followed by a discussion of risk stratification and therapy of pulmonary arterial hypertension (PAH).

Schlüsselwörter

pulmonalarterielle Hypertonie - pulmonale Hypertonie - Leitlinien - Risikostratifizierung

Keywords

pulmonary arterial hypertension - pulmonary hypertension - guidelines - risk stratification

• Literatur

• 1 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618-3731
• 2 Galiè N, Humbert M, Vachiery JL. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119
• 3 Pulido T, Adzerikho I, Channick RN. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818
• 4 Galiè N, Müller K, Scalise AV. et al. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 2015; 45: 1314-1322
• 5 Hoeper MM, Badesch DB, Ghofrani HA. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. New Engl J Med 2023;
• 6 Hoeper MM, Pausch C, Grünig E. et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant 2020; 39: 1435-1444
• 7 McLaughlin VV, Vachiery JL, Oudiz RJ. et al. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J Heart Lung Transplant 2019; 38: 1286-1295
• 8 Galiè N, Barberà JA, Frost AE. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-844
• 9 Sitbon O, Cottin V, Canuet M. et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J 2020; 56: 2000673
• 10 Sitbon O, Channick R, Chin KM. et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522-2533
• 11 Hoeper MM, Al-Hiti H, Benza RL. et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 2021; 9: 573-584
• 12 Rosenkranz S, Pausch C, Coghlan JG. et al. Effects of targeted therapies in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. J Heart Lung Transplant 2023; 42: 102-114